Celyad Oncology SA

4.26-0.3200-6.99%Vol 24.63K1Y Perf -56.85%
Jul 27th, 2021 13:13 DELAYED
BID4.25 ASK4.43
Open4.38 Previous Close4.58
Pre-Market4.37 After-Market-
 -0.21 -4.59%  - -
Target Price
17.00 
Analyst Rating
Strong Buy 1.00
Potential %
285.49 
Finscreener Ranking
 —    -
Insiders Trans % 3/6/12 mo.
-/-/- 
Value Ranking
     42.00
Insiders Value % 3/6/12 mo.
-/-/- 
Growth Ranking
★+     43.06
Insiders Shares Cnt. % 3/6/12 mo.
-/-/- 
Income Ranking
 —    -
Market Cap66.00M 
Earnings Rating
Neutral
Price Range Ratio 52W %
3.64 
Earnings Date
24th Mar 2021

Today's Price Range

4.264.41

52W Range

4.0110.87

5 Year PE Ratio Range

-6.70-5.10

Summary:

Sell

Technical Indicators: Neutral
Moving Averages: Strong Sell
Performance
1 Week
9.83%
1 Month
-16.12%
3 Months
-27.65%
6 Months
-43.67%
1 Year
-56.85%
3 Years
-85.13%
5 Years
-81.23%
10 Years
-

TickerPriceChg.Chg.%
CYAD4.26-0.3200-6.99
AAPL145.95-3.0400-2.04
GOOG2 705.40-87.4900-3.13
MSFT284.04-5.0100-1.73
XOM57.57-0.9100-1.56
WFC45.070.06000.13
JNJ172.380.51000.30
FB365.27-7.1900-1.93
GE13.080.16001.24
JPM151.700.05000.03
Financial StrengthValueIndustryS&P 500US Markets
1.20
1.40
0.08
0.13
-70.40
Leverage Ratio 2.00
ProfitabilityValueIndustryS&P 500US Markets
100.00
-263 946.00
-247 654.00
-111 680.00
-
RevenueValueIndustryS&P 500US Markets
445.00
0.00
-87.15
67.90
Earnings HistoryEstimateReportedSurprise %
----
----
----
----
----
----
----
----
Earnings Per EndEstimateRevision %Trend
6/2019 QR-1.5810.73Positive
12/2019 QR-1.65-0.61Negative
12/2021 FY-1.832.14Positive
12/2022 FY-1.510.00-
Next Report Date-
Estimated EPS Next Report-
Estimates Count-
EPS Growth Next 5 Years %-
Volume Overview
Volume24.63K
Shares Outstanding15.49M
Trades Count98
Dollar Volume95.93K
Avg. Volume38.99K
Avg. Weekly Volume48.71K
Avg. Monthly Volume40.21K
Avg. Quarterly Volume64.85K

Celyad Oncology SA (NASDAQ: CYAD) stock closed at 4.58 per share at the end of the most recent trading day (a -1.29% change compared to the prior day closing price) with a volume of 33.30K shares and market capitalization of 66.00M. Is a component of indices and it is traded on NASDAQ exchange. The company belongs in the Biotechnology industry, Healthcare sector and employs 107 people. Celyad Oncology SA CEO is Filippo Petti.

The one-year performance of Celyad Oncology SA stock is -56.85%, while year-to-date (YTD) performance is -41.28%. CYAD stock has a five-year performance of -81.23%. Its 52-week range is between 4.01 and 10.87, which gives CYAD stock a 52-week price range ratio of 3.64%

Celyad Oncology SA currently has a PE ratio of -1.90, a price-to-book (PB) ratio of 2.09, a price-to-sale (PS) ratio of 161 555.00, a price to cashflow ratio of -, a PEG ratio of 2.32, a ROA of -34.10%, a ROC of -72.58% and a ROE of -73.04%. The company’s profit margin is -%, its EBITDA margin is -247 654.00%, and its revenue ttm is $445.00 , which makes it $0.00 revenue per share.

Of the last four earnings reports from Celyad Oncology SA, there were 0 positive earnings surprise and 0 negative earnings surprise. The company has EPS estimate of $0.00 for the next earnings report. Celyad Oncology SA’s next earnings report date is -.

The consensus rating of Wall Street analysts for Celyad Oncology SA is Strong Buy (1), with a target price of $17, which is +285.49% compared to the current price. The earnings rating for Celyad Oncology SA stock is Neutral (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).

Celyad Oncology SA has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.

Celyad Oncology SA has a Sell technical analysis rating based on Technical Indicators (ADX : 11.20, ATR14 : 0.27, CCI20 : -33.99, Chaikin Money Flow : -0.11, MACD : -0.26, Money Flow Index : 41.66, ROC : -2.76, RSI : 42.87, STOCH (14,3) : 53.77, STOCH RSI : 0.93, UO : 52.39, Williams %R : -46.23), Simple Moving Averages and Exponential Moving Averages.

Aggregated Insider Trades of Celyad Oncology SA in the last 12-months were:

Analyst RatingsCurrent1 M ago3 M ago
Strong Buy
3 (100.00 %)
3 (100.00 %)
3 (100.00 %)
Moderate Buy
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Hold
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Moderate Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Strong Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Summary RatingStrong Buy
1.00
Strong Buy
1.00
Strong Buy
1.00

Celyad Oncology SA

Celyad Oncology is a biopharmaceutical company, specialized in cell therapy. It develops technologies and treatments to treat severe diseases with poor prognosis. The company focuses on Immuno oncology, Cardiology, and Medical devices. Its main product candidates include CAR-T and C-Cure. The firm has CYAD-01 and CYAD-02 programs in pipeline. The company owns trademarks and service marks including CELYAD, C-CATH, C_CURE, CATH and C-CATHez and CARDIO 3 BIOSCIENCES. The firm has Cardiology and Immuno-oncology operating segments.

CEO: Filippo Petti

Telephone: +32 10394100

Address: Rue Edouard Belin 2, Mont-Saint-Guibert 1435, , BE

Number of employees: 107

Bearish or Bullish?
WeekMonthThree MonthsSix Months

Bearish Bullish

50%50%

Bearish Bullish

50%50%

Bearish Bullish

54%46%

Bearish Bullish

56%44%

News

Stocktwits